Eli Lilly and Company (LLY)

Revenue rests on incretin-class medicines: developed originally for type 2 diabetes, they proved effective for weight loss, which opened a fundamentally larger market. Demand ran ahead of manufacturing capacity for a long time, making capacity expansion as important a task for the company as research itself.

Beyond that franchise the portfolio covers oncology, immunology and Alzheimer's disease treatments. Pharmaceutical economics turn on patent protection: while a patent holds, the drug earns high margins; once it lapses, revenue falls quickly under generic pressure. That is why the development pipeline matters more than current sales.

The risks are industry-specific: trial failure, regulatory decisions, and price negotiations with insurers and government. In the United States a distinct factor is the right of federal programmes to negotiate prices on selected drugs. The company pays a dividend while investing heavily in new manufacturing.